Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01235624
Other study ID # UF 8300
Secondary ID 2008-A01238-47
Status Completed
Phase N/A
First received November 4, 2010
Last updated November 5, 2013
Start date March 2009
Est. completion date April 2013

Study information

Verified date November 2013
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

Identify new genes responsible for autosomal dominant retinitis pigmentosa (ADRP), one of the most common causes of hereditary diseases of the retina, and thus better understand the mechanisms involved of the disease."


Description:

Two hundred and fifty samples from unrelated patients, from which 150 were provided by the national reference center of rare disease in Montpellier and 100 recruited in the 9 participating centers over a period of two years."To identify the missing genes, we proceed in two steps. A first step in selecting families negative for the 8 major genes genes, by systematic sequencing of exons most frequently involved. A second step in finding new loci / genes by locus exclusion using microsatellite markers and SNP genotyping.


Recruitment information / eligibility

Status Completed
Enrollment 1161
Est. completion date April 2013
Est. primary completion date April 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 5 Years to 80 Years
Eligibility Inclusion Criteria:

- retinitis pigmentosa diagnosed

- Autosomal dominant transmission diagnosed

- Aged from 5 to 80 years

- Informed consent

- Affiliated or benefit from an insurance regimen

Exclusion Criteria:

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Genetic:
genetic analysis


Locations

Country Name City State
France CHRU Montpellier Montpellier

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Montpellier Ministry of Health, France

Country where clinical trial is conducted

France, 

References & Publications (1)

Audo I, Manes G, Mohand-Saïd S, Friedrich A, Lancelot ME, Antonio A, Moskova-Doumanova V, Poch O, Zanlonghi X, Hamel CP, Sahel JA, Bhattacharya SS, Zeitz C. Spectrum of rhodopsin mutations in French autosomal dominant rod-cone dystrophy patients. Invest O — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary identification of unknown loci and genes responsible of Autosomal dominant retinitis pigmentosa (adRP) for 5 years No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04123626 - A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene Phase 1/Phase 2